IsoTis Accell gains FDA clearance
This article was originally published in The Gray Sheet
Executive Summary
Integra LifeSciences' pending acquisition of orthobiologics firm IsoTis moves a step closer to completion with the Aug. 15 receipt of 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products. Accell is a key asset of the $51 million deal, which was announced Aug. 7 and conditioned upon Accell market go-ahead. The Accell products are indicated for use as bone graft extenders in the spine, extremities and pelvis, or as bone void fillers in the extremities and pelvis (1"The Gray Sheet" Aug. 13, 2007, p. 10)...
You may also be interested in...
Integra Buys IsoTis, Gains Accell Demineralized Bone Matrix In $51 Mil. Deal
Closure of Integra LifeSciences' acquisition of orthobiologics firm IsoTis is conditioned upon 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products, Integra says
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.